



Detection of *H. pylori* IgG by Using ELISA

Malabika Mahato^{1*}

¹Department of Pathology, Sree Balaji Medical College and Hospital,
Bharath Institute of Higher Education and Research, Chennai, Tamil Nadu, India.

Authors' contributions

The sole author designed, analysed, interpreted and prepared the manuscript.

Article Information

DOI: 10.9734/JPRI/2020/v32i2130759

Editor(s):

(1) Dr. Giuseppe Murdaca, University of Genoa, Italy.

Reviewers:

(1) Ahmed Sattar Abood, Al-Iraqia University, Iraq.

(2) Fatima Lami Ciroma, Kaduna State University, Nigeria.

(3) Davoud Esmaeili, Baqiyatallah University of Medical Sciences, Iran.

Complete Peer review History: <http://www.sdiarticle4.com/review-history/60123>

Original Research Article

Received 24 June 2020
Accepted 28 August 2020
Published 07 September 2020

ABSTRACT

Background: *Helicobacter pylori* is a Gram-negative, winding, microaerophilic human pathogen and have indicated solid relationship with different gastroduodenal illnesses. Its contagion is one of the most widely recognized interminable diseases in humans since the isolation of the pathogen (1–3).

Aim and Objectives: This examination was directed to discover the affectability and particularity of ELISA in distinguishing *H. pylori*.

Materials and Methods: The investigation was completed in the Department of Pathology, Sri Balaji Medical College and Hospital, Chennai for a period from November 2016 to October 2018. The research was planned as Prospective study. The study recruited two population of respondents comprising of 50 symptomatic clinicians and 50 infection populations of either sex, over 18 years of age. Patients with signs identified with the upper gastrointestinal tract prompted by endoscopic examination and identified as having gastritis, peptic ulcer (PU) and those patients were recalled for this investigation. Patients who took treatment of pylori destruction and use of antimicrobial agents, neutron siphon agonists, bismuth containing mixtures during the month prior to endometrial biopsy were removed from the inquiry. All essential history, clinical breakthroughs and research facility records of each subject were methodically documented in Microsoft windows sensitive Excel sheet for the consequent examination. Arterial blood samples were collected for the Enzyme Linked Immunosorbent Assay (ELISA) test. For this, 50 people of either sex matured over 18 years of age were considered.

*Corresponding author: E-mail: deanpublications@bharathuniv.ac.in;

Results: It was observed that, the normal age of the patient was 40 to 60 years, 56% of them were male and 44% female. In this examination, serology tests to recognize IgG counter acting agent demonstrated the affectability of (60%). By and large, low precision and affectability of IgG serological tests is because of the failure to separate among present and past disease. **Conclusion:** These examinations show that *H. pylori* contamination is a typical issue among individuals in tamilnadu, India. The titer of IgG antibodies to *H. pylori* in serum can be utilized as non-intrusive tests for the presence of gastritis.

Keywords: *Helicobacter pylori*; IgG; seroprevalence; ELISA.

1. INTRODUCTION

Helicobacter pylori is a gram-negative, winding, microaerophilic human pathogen that have been associated with different gastroduodenal sicknesses. The infection is one of the most well-known incessant diseases in humans since isolation of the pathogen [1]. Barry Marshall and Robin Warren of Perth, Western Australia found *H. pylori* in 1982 [2]. Since its discovery *H.pylori* has been widely studied in the fields of pathology and microbiology. As of now, over a large portion of the total population was affected with *H. pylori*, which is the significant reason for constant gastritis and peptic ulcer [3]. *H. pylori* contamination assumes a noticeable causative job for gastric disease; which is being the fourth most normal malignancy and the subsequent driving reason for malignancy related deaths world-wide (WCRF, 1997) [4].

Commonly, all *Helicobacter* species express urease proteins, a chemical that is fundamental for microbial endurance [5]. Test erasure of the urease quality renders *H. pylori* unfit to colonize gastric mucosa. Urease is an intracellular chemical that is bound to the external layer of other microscopic organisms upon bacterial lyses [6].

The source of *H. Pylori* transmission course is restricted. The transmission courses have been proposed to be blends of oral-oral, gastro-oral or fecal oral transmission because of absence of access to clean drinking water and legitimate sanitation (13).The NIH (National Institute of Health) General agreement Development Committee on *Candida albicans* in Peptic Ulcer Disease recommends that the inference should be drawn before care is initiated. [7].

Different tests have been created to analyze *H. pylori* that show changing exactness, explicitness and plausibility for use in clinical practice or in research. Different tests have certain focal points and impediments, and the decision of test(s) to

be utilized is subject to numerous elements, for example, for clinical or research use [8]. All in all the tests need either an intercession, for example, a biopsy from an endoscopic assessment, or a fringe test, for example, blood tests for identifying *H. pylori* antibodies, or antigen as well as antibodies tests from tests from saliva, urine and /or faeces, or identification of urea in terminated air-breath [9].

Serological tests measure the course of IgG, IgM and IgA antigens to *H.pylori* and have a significant efficacy. The proximity or non-compliance of IgM antibodies to *H.pylori* may reflect the existence of severe toxicity [10]. IgG level assurance can be a substantial testing technique. Confirmatory testing is not important for follow-up on the ground that mitigating agent titers may not decay for 6 to 1 year or once in a while because for a number of years after therapy. The definite role of confirmatory testing in the implementation of infection of *Helicobacter pylori* has yet to be established, despite the fact that it exists [11].

2. MATERIALS AND METHODS

The examination was done in the Department of Pathology, Sri Balaji Medical College and Hospital, Chennai for a period from November 2016 to October 2018. The investigation was planned as Prospective investigation. Two population groups were enrolled for the investigation. A total of 50 symptomatic patients and 50 asymptomatic respondents of both sex, adults of above 18 years were recruited for the study. Patients with an assortment of indications identified by upper gastrointestinal tract symptoms prescribed by physicians for endoscopic assessment, and who were consequently diagnosed with gastritis and/or peptic ulcer (PU) were enrolled for this investigation [12].

Patients taking *H. pylori* eradication treatment and those currently on anti-microbials, proton

siphon inhibitors, bismuth containing mixes or sucralfate within a month before the endoscopy were excluded from the study. All pertinent history, clinical discoveries and research facility records of each subject was efficiently recorded in a Microsoft delicate Excel Sheet for consequent analyses. Venous blood samples were used for the ELISA assay [13].

ELISA test for Detection *H.pylori* IgG: Serum hostile to *H. pylori* IgG was distinguished by ELISA *H.pylori* IgG Kit. The Kit was made by CALBIOTECH, India. List No. HP013G. Test methodology was according to pack manual.

2.1 Standard of the Test

Patient serum was added to wells covered with cleaned antigen. IgG explicit counter acting agent If present, bind it to the antigen. Every single unbound stuff washed away and the compound conjugate was added to the antigen-immune response complicated, if introduce. Overabundance Conjugate is cleaned off and the membrane is also included. The plate was cloned to allow the membrane to be hydrolysed by the protein. The force of the shading created is relative to the measure of IgG explicit immune response in the example [14].

2.2 Test Procedure

The ideal number of covered strips was placed into the holder. Negative control, positive control and calibrator were prepared to utilize. 10µl of the sample to 200 µl of test diluents was blended well. Dispensed 100 µl of sera, calibrator and controls into the proper wells and incubated for 20 minutes at room temp. Washed wells multiple times with 300 µl of 1x wash support. Then dispensed 100µl chemical conjugate to each well and brood for 20 minutes at room temp. Again washed wells multiple times with 300 µl of 1x wash support. Dispensed 100µl TMB substrate and incubate for 10 minutes at room temperature and added 100µl of stop solution. O.D at 450 nm was measured. A double wave length is prescribed with reference channel of 600-650 nm [15].

3. RESULTS AND DISCUSSION

Calculated the cut off worth; calibrator OD x calibrator factor (CF) and Ab (counter acting agent) list of every assurance by partitioning the OD estimation of each example by cut off worth.

Case of Typical outcomes:

Calibrator mean OD = 0.8

Calibrator Factors = 0.5

Cut off worth = 0.8 x 0.5 = 0.400

Positive control OD = 1.2

Stomach muscle Index = 1.2/0.4 = 3

Quiet example OD = 1.6

Stomach muscle Index = 1.6/0.4 = 4.0

Stomach muscle Index Interpretation:

<0.9 No discernible immune response to H.Pylori IgG by ELISA

0.9 – 1.1 Broad line positive follow up the testing is prescribed if clinically demonstrated.


Table shows sensitivity of ELISA in symptomatic patient’s blood serum was 60% and specificity of ELISA test was observed 90% in asymptomatic group sample.

$\chi^2 = 27.4725$ and P value = <0.0001 by chi square test, result is significant.

Serological assays for *H. pylori* are based either on whole-cell sonicate antigen or on one or several purified components of the bacterium as the antigen. A majority of serological studies are now conducted with commercial kits that have been evaluated in developed countries. These commercial kits are often too expensive for developing countries, and use of a validated in-house enzyme-linked immunosorbent assay (ELISA) based on sonicated antigens would be preferable [16, 17].

Table 1. Sensitivity and specificity of ELISA test in 50 symptomatic & asymptomatic case sensitivity and specificity of ELISA Anti-*H. pylori* IgG

Test results	Symptomatic group (n=50)	Asymptomatic group (n=50)	Sensitivity	Specificity
ELISA Positive	30	5	60%	90%
ELISA Negative	20	45		
Total	50	50		



Graph 1. Sensitivity and specificity of ELISA test in 50 symptomatic and asymptomatic case Sensitivity and Specificity of ELISA Anti-*H. pylori* IgG

It was discovered that, the normal age of the patient was 40 to 60 years. 56% of them were male and 44% female [18]. In this investigation, serology tests to distinguish IgG immune response demonstrated the affectability of (60%). For the most part, low precision and affectability of IgG serological tests is because of the powerlessness to separate among present and past disease.

4. CONCLUSION

High *H. pylori* antibodies, that got from these examinations demonstrates that *H.pylori* contamination is as yet a typical issue among individuals in tamilnadu, India. The titer of IgG counter acting agent to *H.pylori* in understanding serum can be utilized as non-intrusive tests for the presence of gastritis.

CONSENT

As per international standard or university standard, patients' written consent has been collected and preserved by the author(s).

ETHICAL APPROVAL

This investigation and study endorsed by Ethical Committee of Sri Balaji Medical College and Hospital.

COMPETING INTERESTS

Author has declared that no competing interests exist.

REFERENCES

1. Dutta D, Clevers H. Organoid culture systems to study host-pathogen interactions. *Current Opinion in Immunology*; 2017.
2. Kumari PR. A study of Helicobacter pylori in gastroduodenal diseases. *Int J Curr Microbiol Appl Sci*; 2014.
3. Ogihara A, Kikuchi S, Hasegawa A, Kurosawa M, Miki K, Kaneko E, et al. Relationship between Helicobacter pylori infection and smoking and drinking habits. *J Gastroenterol Hepatol*; 2000.
4. Marshall B, Azad M. Q&A: Barry Marshall. A bold experiment. *Nature*; 2014.
5. D'Elis MM. [Helicobacter pylori, the story so far]. *Med Secoli*; 2007.
6. Sipponen P, Price AB. The Sydney System for classification of gastritis 20 years ago. *Journal of Gastroenterology and Hepatology (Australia)*; 2011.
7. Kusters JG, Van Vliet AHM, Kuipers EJ. Pathogenesis of Helicobacter pylori infection. *Clin Microbiol Rev*; 2006.

8. Cover TL, Blaser MJ. Helicobacter pylori in Health and Disease. Gastroenterology; 2009.
9. Wroblewski LE, Peek RM, Wilson KT. Helicobacter pylori and gastric cancer: Factors that modulate disease risk. Clinical Microbiology Reviews; 2010.
10. Ahmed N, Tenguria S, Nandanwar N. Helicobacter pylori--a seasoned pathogen by any other name. Gut Pathog; 2009.
11. Exner MM, Doig P, Trust TJ, Hancock REW. Isolation and characterization of a family of porin proteins from Helicobacter pylori. Infect Immun; 1995.
12. Carlini CR, Ligabue-Braun R. Ureasas as multifunctional toxic proteins: A review. Toxicon; 2016.
13. Vale FF, Vitor JMB. Transmission pathway of Helicobacter pylori: Does food play a role in rural and urban areas? International Journal of Food Microbiology; 2010.
14. Gralnek I, Dumonceau J-M, Kuipers E, Lanas A, Sanders D, Kurien M, et al. Diagnosis and management of nonvariceal upper gastrointestinal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy; 2015.
15. Gralnek IM, Dumonceau JM, Kuipers EJ, Lanas A, Sanders DS, Kurien M, et al. Diagnosis and management of nonvariceal upper gastrointestinal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy; 2015.
16. Fock KM, Katelaris P, Sugano K, Ang TL, Hunt R, Talley NJ, et al. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol; 2009.
17. Patel SK, Pratap CB, Jain AK, Gulati AK, Nath G. Diagnosis of Helicobacter pylori: What should be the gold standard? World J Gastroenterol. 2014;20(36): 12847-59.
18. Ochola LB, Vounatsou P, Smith T, Mabaso MLH, Newton CRJC. The reliability of diagnostic techniques in the diagnosis and management of malaria in the absence of a gold standard. Lancet Infect Dis; 2006.

© 2020 Mahato; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:
The peer review history for this paper can be accessed here:
<http://www.sdiarticle4.com/review-history/60123>